COURT-RULING ·Filed May 18, 2026
Court ruling (appellate)
Actionable Insight • Neutral
This ruling closes a minor product liability case with no financial impact on AbbVie. No market reaction expected. Monitor for any Illinois Supreme Court appeal petition, though unlikely given the record.
Final — all horizons settled through T+60d
ABBV ▲ +18.79% at T+60d
NEUTRAL call ✓ call won +18.79% · α vs SPY +13.94% · entry $209.41 → $248.76
T+1d
+2.08%
call +2.08% · α +2.73%
$213.76
settled 5mo ago
T+5d
+1.77%
call +1.77% · α +0.15%
$213.12
settled 4mo ago
T+20d
+6.24%
call +6.24% · α +4.66%
$222.47
settled 4mo ago
T+60d
+18.79%
call +18.79% · α +13.94%
$248.76
settled 7w ago
Price Chart
Loading chart...
Executive Summary
The Illinois Appellate Court affirmed summary judgment for AbbVie in a product liability case over its XEN gel stent. The plaintiff failed to provide expert testimony that a manufacturing defect caused his injuries, ending the litigation in AbbVie's favor.
Court Ruling Details
Ruling Date
May 18, 2026
Court
Appellate Court of Illinois, Third District
Court Level
Appellate
Judge
Justice Brennan
Case Type
product liability
Ruling Type
final judgment
Outcome
WIN — ruling favors this company
Will It Be Appealed?
Unlikely
Precedent Risk
LOW
Key Facts
- Appellate court affirmed summary judgment for AbbVie in strict product liability action.
- Plaintiff alleged XEN gel stent had chemical residue causing eye injuries but lacked expert causation evidence.
- Non-precedential order under Illinois Supreme Court Rule 23(e)(1).
- No damages awarded, no injunction, no class action.
Financial Impact
No damages awarded; litigation costs immaterial relative to $371.7B market cap.
Risk Factors
- Potential plaintiff appeal to Illinois Supreme Court is low probability and would not change outcome without expert evidence.
Market Snapshot
Price
$209.56
Volume
100
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
75% bullish (40 analysts)
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-3c4wl60q-ABBV |
14 reports for ABBV
100% Hit rate best @ T+60▲ +27.21%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | Court Ruling | $261.77 $264.48 | ▲ +1.04% | ▼ −0.62% | $259.93 (−0.70%) |
Sep 3, 2026 29d ago | 8-K | $260.21 $257.12 | ▼ −1.19% | ▼ −0.04% | $259.93 (−0.11%) |
Aug 5, 2026 8w ago | 8-K | $243.87 $250.82 | ▲ +2.85% | ▲ +1.64% | $259.93 (+6.59%) |
Aug 3, 2026 8w ago | Institutional Cluster | $245.10 $247.97 | ▲ +1.17% | ▼ −0.86% | $259.93 (+6.05%) |
Aug 3, 2026 8w ago | Court Ruling | $245.10 $247.97 | ▲ +1.17% | ▼ −0.86% | $259.93 (+6.05%) |
Jul 31, 2026 9w ago | 8-K | $250.94 $246.04 | ▼ −1.95% | ▼ −5.46% | $259.93 (+3.58%) |
Jul 27, 2026 9w ago | Court Ruling | $256.91 $250.94 | ▼ −2.32% | ▼ −3.40% | $259.93 (+1.18%) |
Jun 22, 2026 14w ago | 8-K | $230.01 $254.31 | ▲ +10.56% | ▲ +11.02% | $259.93 (+13.01%) |
May 18, 2026 19w ago | Court Ruling | $209.41 $213.12 | ▲ +1.77% | ▲ +0.15% | $259.93 (+24.12%) |
Apr 29, 2026 22w ago | 8-K | $203.89 $206.11 | ▲ +1.09% | ▼ −2.02% | $259.93 (+27.49%) |
Showing 10 of 14
US Market Status
Market Closed — Opens in 40m
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access